Treating pulmonary arterial hypertension: Current treatments and future prospects

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 6, 2011, Pages 359-370

  Raja, Shahzad G ^a   Raja, Shahbaz M ^b  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b MAYO HOSPITAL   (Pakistan)

Author keywords

Endothelin 1; Pulmonary hypertension; Vascular endothelium; Vascular smooth muscle

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADRENOMEDULLIN; AMBRISENTAN; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; ILOPROST; IMATINIB; MACITENTAN; NIFEDIPINE; PHOSPHODIESTERASE I; PLACEBO; PROSTACYCLIN; PROSTANOID; RHO KINASE INHIBITOR; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNINDEXED DRUG; UNIPROST; VARDENAFIL; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; WARFARIN;

ADJUVANT THERAPY; COUGHING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; HEADACHE; HEART FUNCTION TEST; HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; IDIOPATHIC DISEASE; JAW PAIN; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; NOSE CONGESTION; OXYGEN THERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84859062408     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311420773     Document Type: Article

References (74)

1. Baker S.E. Hockman R.H. (2005) Inhaled iloprost in pulmonary hypertension. Ann Pharmacother 39: 1265–1274.
2. Barst R.J. Langleben D. Badesch D. Frost A. Lawrence E.C. Shapiro S. et al. for the STRIDE-2 Study Group. (2006) Treatment of pulmonary arterial hypertension with the selective endothelin: a receptor antagonist sitaxsentan. J Am Coll Cardiol 47: 2049–2056.
3. Barst R.J. Langleben D. Frost A. Horn E.M. Oudiz R. Shapiro S. et al. for the STRIDE-1 Study Group. (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169: 441–447.
4. Barst R.J. McGoon M. McLaughlin V. Tapson V. Rich S. Rubin L. et al. for the Beraprost Study Group. (2003) Beraprost for pulmonary arterial hypertension. J Am Coll Cardiol 41: 2119–2125.
5. Barst R.J. Rubin L.J. Long W.A. McGoon M.D. Rich S. Badesch D.B. et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296–302.
6. Brindle N.P. Saharinen P. Alitalo K. (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98: 1014–1023.
7. Chhina M.K. Nargues W. Grant G.M. Nathan S.D. (2010) Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol 6: 19–35.
8. Chin K.M. Rubin L.J. (2008) Pulmonary arterial hypertension. J Am Coll Cardiol 51: 1527–1538.
9. Cox C.P. Linden J. Said S.I. (1984) VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 5: 325–328.
10. Doe C. Bentley R. Behm D.J. Lafferty R. Stavenger R. Jung D. et al. (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 320: 89–98.
11. Falk J.A. Philip K.J. Schwarz E.R. (2010) The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag 6: 273–280.
12. Farber H.W. Loscalzo J. (2004) Pulmonary arterial hypertension. N Engl J Med 351: 1655–1665.
13. Frank H. Mlczoch J. Huber K. Schuster E. Gurtner H.P. Kneussl M. (1997) The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112: 714–721.
14. Fujita H. Fukumoto Y. Saji K. Sugimura K. Demachi J. Nawata J. et al. (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels Vol. 25: 144–149.
15. Galiè N. Brundage B.H. Ghofrani H.A. Oudiz R.J. Simonneau G. Safdar Z. et al. for the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. (2009) Tadalafil therapy for pulmonary hypertension. Circulation 119: 2894–2903.
16. Galiè N. Ghofrani H.A. Torbicki A. Barst R.J. Rubin L.J. Badesch D. et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157.
17. Galiè N. Humbert M. Vachiéry J.L. Vizza C.D. Kneussl M. Manes A. et al. for the Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39: 1496–1502.
18. Galiè N. Olschewski H. Oudiz R.J. Torres F. Frost A. Ghofrani H.A. et al. for the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117: 3010–3019.
19. Ghofrani H.A. Hoeper M.M. Halank M. Meyer F.J. Staehler G. Behr J. et al. (2010 a) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 36: 792–799.
20. Ghofrani H.A. Morrell N.W. Hoeper M.M. Olschewski H. Peacock A.J. Barst R.J. et al. (2010 b) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171–1177.
21. Ghofrani H.A. Seeger W. Grimminger F. (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412–1413.
22. Greenway S. van Suylen R.J. Du Marchie Sarvaas G. Kwan E. Ambartsumian N. Lukanidin E. et al. (2004) S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 164: 253–262.
23. Grimminger F. Weimann G. Frey R. Voswinckel R. Thamm M. Bölkow D. et al. (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33: 785–792.
24. Haydar S. Sarti J.F. Grisoni E.R. (2007) Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension. J Pediatr Surg 42: 758–764.
25. Horio T. Kohno M. Kano H. Ikeda M. Yasunari K. Yokokawa K. et al. (1995) Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res 77: 660–664.
26. Ichiki Y. Kitamura K. Kangawa K. Kawamoto M. Matsuo H. Eto T. (1994) Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 338: 6–10.
27. Iglarz M. Binkert C. Morrison K. Fischli W. Gatfield J. Treiber A. et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327: 736–745.
28. Ishikura K. Yamada N. Ito M. Ota S. Nakamura M. Isaka N. et al. (2006) Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174–178.
29. Jing Z.C. Jiang X. Wu B.X. Xu X.Q. Wu Y. Ma C.R. et al. (2009) Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 95: 1531–1536.
30. Jing Z.C. Yu Z.X. Shen J.Y. Wu B.X. Xu K.F. Zhu X.Y. et al. for the Efficacy and safety of VArdenafiL in the treatment of p Ulmonary Arterial hyperTensION (EVALUATION) Study Group. (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 183: 1723–1729.
31. Kakishita M. Nishikimi T. Okano Y. Satoh T. Kyotani S. Nagaya N. et al. (1999) Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 96: 33–39.
32. Kano H. Kohno M. Yasunari K. Yokokawa K. Horio T. Ikeda M. et al. (1996) Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 14: 209–213.
33. Kitamura K. Kangawa K. Kawamoto M. Ichiki Y. Nakamura S. Matsuo H. et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192: 553–560.
34. Leuchte H.H. Baezner C. Baumgartner R.A. Bevec D. Bacher G. Neurohr C. et al. (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32: 1289–1294.
35. Li M. Liu Y. Dutt P. Fanburg B.L. Toksoz D. (2007) Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 293: L463–L471.
36. Maruno K. Absood A. Said S.I. (1995) VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol 268: L1047–L1051.
37. McLaughlin V.V. Archer S.L. Badesch D.B. Barst R.J. Farber H.W. Lindner J.R. et al. (2009) ACCF/AHA. ACCF / AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250–2294.
38. McLaughlin V.V. Shillington A. Rich S. (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477–1482.
39. McMurtry M.S. Archer S.L. Altieri D.C. Bonnet S. Haromy A. Harry G. et al. (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479–1491.
40. Murphey L.M. Hood E.H. (2003) Bosentan and warfarin interaction. Ann Pharmacother 37: 1028–1031.
41. Murthy S.N. Nossaman B.D. Kadowitz P.J. (2010) New approaches to the treatment of pulmonary hypertension: from bench to bedside. Cardiol Rev 18: 76–84.
42. Nagaoka T. Morio Y. Casanova N. Bauer N. Gebb S. McMurtry I. et al. (2004) Rho / Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287: L665–L672.
43. Nagaya N. Satoh T. Nishikimi T. Uematsu M. Furuichi S. Sakamaki F. et al. (2000) Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101: 498–503.
44. Nossaman B.D. Feng C.J. Cheng D.Y. Dewitt B.J. Coy D.H. Murphy W.A. et al. (1995) Comparative effects of adrenomedullin, an adrenomedullin analog, and CGRP in the pulmonary vascular bed of the cat and rat. Life Sci 56: PL63–PL66.
45. Nossaman B.D. Feng C.J. Kaye A.D. de Witt B. Coy D.H. Murphy W.A. et al. (1996) Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol 270: L782–L789.
46. Olschewski H. Simonneau G. Galiè N. Higenbottam T. Naeije R. Rubin L.J. et al. Aerosolized Iloprost Randomized Study Group. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322–329.
47. Owji A.A. Smith D.M. Coppock H.A. Morgan D.G. Bhogal R. Ghatei M.A. et al. (1995) An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat. Endocrinology 136: 2127–2134.
48. Patterson K.C. Weissmann A. Ahmadi T. Farber H.W. (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145: 152–153.
49. Petkov V. Mosgoeller W. Ziesche R. Raderer M. Stiebellehner L. Vonbank K. et al. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339–1346.
50. Raja S.G. (2010 a) Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther 28: e65–e71.
51. Raja S.G. (2010 b) Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 11: 1066–1073.
52. Raja S.G. Danton M.D. MacArthur K.J. Pollock J.C. (2006) Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. J Cardiothorac Vasc Anesth 20: 722–735.
53. Raja S.G. Dreyfus G.D. (2008) Current status of bosentan for treatment of pulmonary hypertension. Ann Card Anaesth 11: 6–14.
54. Raja S.G. Nayak S.H. (2004) Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 78: 1496–1506.
55. Rich S. Kaufmann E. Levy P.S. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81.
56. Rich S. Seidlitz M. Dodin E. Osimani D. Judd D. Genthner D. et al. (1998) The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114: 787–792.
57. Rubin L.J. Badesch D.B. Barst R.J. Galie N. Black C.M. Keogh A. et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903.
58. Ryerson C.J. Nayar S. Swiston J.R. Sin D.D. (2010) Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 11: 12
59. Said S.I. Hamidi S.A. Dickman K.G. Szema A.M. Lyubsky S. Lin R.Z. et al. (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260–1268.
60. Schermuly R.T. Janssen W. Weissmann N. Stasch J.P. Grimminger F. Ghofrani H.A. (2011) Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 20: 567–576.
61. Schermuly R.T. Pullamsetti S.S. Kwapiszewska G. Dumitrascu R. Tian X. Weissmann N. et al. (2007) Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115: 2331–2339.
62. Shimokawa H. Takeshita A. (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767–1775.
63. Simonneau G. Barst R.J. Galie N. Naeije R. Rich S. Bourge R.C. et al. for the Treprostinil Study Group. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary artery hypertension. Am J Respir Crit Care Med 165: 800–804.
64. Sitbon O. Humbert M. Jaïs X. Ioos V. Hamid A.M. Provencher S. et al. (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105–3111.
65. Sitbon O. Humbert M. Nunes H. Parent F. Garcia G. Hervé P. et al. (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780–788.
66. Souza R. Sitbon O. Parent F. Simonneau G. Humbert M. (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61: 736
67. Takemoto M. Sun J. Hiroki J. Shimokawa H. Liao J.K. (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57–62.
68. Treiber A. Schneiter R. Hausler S. Stieger B. (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400–1407.
69. Tuder R.M. Chacon M. Alger L. Wang J. Taraseviciene-Stewart L. Kasahara Y. et al. (2001) Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195: 367–374.
70. Tuder R.M. Flook B.E. Voelkel N.F. (1995) Increased gene expression for VEGF and the VEGF receptors KDR / Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798–1807.
71. van Giersbergen P.L. Treiber A. Clozel M. Bodin F. Dingemanse J. (2002) In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71: 253–262.
72. Wanstall J.C. Gambino A. Jeffery T.K. Cahill M.M. Bellomo D. Hayward N.K. et al. (2002) Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res 55: 361–368.
73. Weigand L. Sylvester J.T. Shimoda L.A. (2006) Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 290: L284–L290.
74. Yu Y. Fantozzi I. Remillard C.V. Landsberg J.W. Kunichika N. Platoshyn O. et al. (2004) Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 101: 13861–13866.